Global Preimplantation Genetic Testing Market Growth Factors Improving Clinical Outcomes, Enhancements Business Analysis

Preimplantation Genetic Testing Market Growth, Trends and Size Analysis by Procedure (Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening), Type (Chromosomal Abnormalities, X-linked Diseases, Embryo Testing, Aneuploidy Screening, LA Typing and others), Application (Embryo HLA Typing for Stem Cell Therapy, IVF Prognosis, Late-Onset Genetic Disorders, Inherited Genetic Disease and others), Technology (Next-Generation Sequencing, Polymerase Chain Reaction, Fluorescence in Situ Hybridization, Comparative Genomic Hybridization, Single-Nucleotide Polymorphism), Product and Service (Reagents and Consumables, Instruments, Software and Services) - Global Forecast till 2027Market HighlightsIt is estimated that the global preimplantation genetic testing market is expected to register a CAGR of 10.2% during the forecast period of 2019 to 2025, with a market value of USD 375.8 million in 2018.Preimplantation genetic testing is the testing at the pre-implantation stage for detection of genetic defects in embryos or oocytes.

Preimplantation genetic testing has occurred more frequently in recent years in North America and Europe, due to the advancement in genetic technology.The decreasing fertility rates worldwide enhance the acceptance of the preimplantation genetic testing to avoid further complications of chromosomal abnormalities with advancing maternal age.

This leads to the growth of the preimplantation genetic testing market during the forecast period.

According to the Vital Statistics Rapid Release, the total fertility rate for the US in 2017 was 1,764.5 births per 1,000 women, and in 2016 it was 1,820.5,  which is 3% less, this shows the reduction in the rate of fertility.An increasing number of fertility clinics worldwide, new development technological advancements in the field of genetic analysis and high threat of chromosomal abnormalities with advancing maternal age are the other driving factors for global preimplantation genetic testing marketRequest Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/8121 SegmentationThe global preimplantation genetic testing market is segmented based on procedure, type, application, technology, product and service, end user, and region.The global market for preimplantation genetic testing, by procedure, is segmented into preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS).

The market by end user has been segmented into maternity centers & fertility clinicshospitals, diagnostic labs and research laboratories & academic institutes.

Based on region, the global preimplantation genetic testing market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.Key PlayersSome of the major players in the global preimplantation genetic testing market are Natera, Inc.CooperSurgical, Inc., F. Hoffmann-La Roche AG, Illumina, Inc., IGENOMIX, Reprogenetics, LLC, Genea Limited, PerkinElmer, Inc., Genesis Genetics Ltd., Quest Diagnostics Incorporated, Thermo FisherScientific, Inc, Bioarrayn Genetics, Laboratory Corporation of America Holdings, California Pacific Medical Center and Reproductive Health Science LtdRegional AnalysisThe market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The market intelligence study on the Global Preimplantation Genetic Testing Market has been designed by analyzing the market essentials and conducting extensive research into different aspects of the industry.

The popular worldwide trend focusing on the presence of natural ingredients in food and beverages is on the rise.

The escalating demand for healthier substitutes for different food ingredients, especially innovative products such as plant-based meat alternatives, are paving the way for technological innovations and increasing the scope of food engineering.To get a sample pdf with the skeleton of the Global Preimplantation Genetic Testing Market Report, click here: https://www.reportsanddata.com/sample-enquiry-form/2244 In market segmentation by manufacturers, the report covers the following companies :- PGT services include Natera, Inc.; CooperSurgical, Inc.; F. Hoffmann-La Roche AG; Illumina, Inc.; IGENOMIX; and othersKey players functioning in the food and beverage industry are also resorting to inventive methods to extend their consumer base.

Digital media and social networking platforms have proven effective for companies attempting to broaden their reach in a way that is non-intrusive yet persuasive customers to consider regular purchases.

With the increasing integration of social media in consumers’ daily lives and the ever-expanding virtual marketplace, the Keyword industry has witnessed the growth of several profitable growth opportunities and paving the way for more product innovation.Scope of the Report:To help gain the business owner further gain business intelligence the study on the Preimplantation Genetic Testing Market for the forecast period 2019 - 2026 brings to light data on production capability, consumption capacity, spending power, investment feasibility, and technology innovation.

The study offers regional profiles of major vendors and extensive country-level break down to empower companies to make a wise investment decision when exploring new regions.Test Type (Revenue, USD Million; 2019–2026)Preimplantation Genetic Diagnosis (PGD)Preimplantation Genetic Screening (PGS)Type (Revenue, USD Million; 2019–2026)Chromosomal AbnormalitiesX-linked DiseasesEmbryo Testing (Fresh Embryo (Own Eggs), Frozen Embryo (Own Eggs), Fresh Embryo (Donor Eggs), Frozen Embryo (Donor Eggs))Aneuploidy ScreeningHLA TypingOther PGT TypesApplication (Revenue, USD Million; 2019–2026)Embryo HLA Typing for Stem Cell TherapyIVF PrognosisLate Onset Genetic DisordersInherited Genetic DiseaseOthersEnd Use (Revenue, USD Million; 2019–2026)Maternity Centers & Fertility ClinicsHospitals, Diagnostic Labs, and Service ProvidersResearch Laboratories & Academic InstitutesClick here to Get customization & check available discount for the report @ https://www.reportsanddata.com/discount-enquiry-form/2244Geographically, this report studies the top producers and consumers in these key regions:North AmericaEuropeAsia PacificMiddle East & AfricaLatin AmericaGlobal Competitive Landscape:The key participants that control a considerable portion of the Preimplantation Genetic Testing Market are actively employing the resources at their disposal to bring about long-standing development changes.

According to a new market research report "Preimplantation Genetic Testing Market by Type (Genetic Diagnosis/Genetic Screening), Technology (NGS, PCR, FISH, CGH, SNP), Products & Services, Application (Aneuploidy, Translocations), End User (Fertility Clinics, Research) - Forecast to 2022", published by MarketsandMarkets™, the Global Preimplantation Genetic Testing Market is projected to reach USD 541.8 Million by 2022 from USD 336.4 Million in 2017, at a CAGR of 10.0%.Browse and in-depth TOC on " Preimplantation Genetic Testing Market "85 - Tables42 - Figures204- PagesDownload PDF Brochure:- http://www.marketsandmarkets.com/pdfdownload.asp?id=605By application, the aneuploidy segment is expected to be the fastest growing segment in the forecast period The aneuploidy segment is expected to grow at the fastest CAGR.

Growth of this segment can be attributed to the increasing maternal age, rising incidence of aneuploidy disorders, and strategic initiatives by key players to provide technologically advanced PGS products for aneuploidy screening.Aneuploidy screening has been reported to increase the chance of successful embryo implantation, decreases miscarriage rate, and reduce the chance of having a child with a chromosome abnormality).North America dominated the market in 2016 Geographically, the Preimplantation Genetic Testing Market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World.

North America accounted for the largest share of the market in 2016, followed by Europe.

Rising number of IVF procedures (with decreasing fertility rates), significant adoption of genomic techniques, ongoing trend of replacing traditional genomic technologies with advanced and innovative genetic techniques (such as FISH and NGS), and increasing private-public funding to develop and commercialize novel PGS & PGD procedures are the key factors that account for the larger share of the Preimplantation Genetic Testing Market in North America.Talk To Our Research Analysts: -http://www.marketsandmarkets.com/speaktoanalyst.asp?id=605As of 2016, the major product manufacturers operating in the global Preimplantation Genetic Testing Market included Illumina, Inc. (U.S.), CooperSurgical, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Abbott Laboratories (U.S.), Natera, Inc. (U.S.), Rubicon Genomics, Inc. (U.S.), Oxford Gene Technology (U.K.), Yikon Genomics (China), and SciGene Corporation (U.S.), among others.

Moreover, as of 2016, major service providers active in the global market included Beijing Genomics Institute (BGI) (China), Good Start Genetics (U.S.), CombiMatrix Corporation (U.S.), Genea Limited (Australia), Invicta Genetics (Poland), and Progenesis (U.S.). 

April 16, 2019: The global preimplantation genetic testing market is expected to reach USD 107.3 million by 2024, at a CAGR of 6.2% over the forecast period, according to a new report by Radiant Insights, Inc.

It is primarily driven by a rising awareness among couples to undergo diagnostic and screening tests to minimize genetic diseases and aneuploidy in fetus.

The ability of preimplantation genetic testing to detect genetic disorders and rare diseases, such as fibro dysplasia ossificans progressive, is anticipated to propel the growth.High adoption of In Vitro Fertilization (IVF) technique consequently upsurges the utilization of Preimplantation Genetic Diagnosis (PGD).

These techniques are advantageous in a way that they allow the development of a healthy fetus and prevent the risk of selective pregnancy termination.

Hence, PGT acts as an addendum to assisted reproductive technology.A substantial number of patients with infertility and impaired fecundity are recommended to embrace IVF therapy in combination with PGT procedures, which in turn is expected to stimulate the growth.

In addition, public and private authorities are promoting reproductive health by undertaking initiatives is also anticipated to drive the Preimplantation Genetic Testing (PGT) (PGS/PGD) market.Request a Free Sample Copy of Preimplantation Genetic Testing (PGT) (PGS/PGD) Market Report @ https://www.radiantinsights.com/research/preimplantation-genetic-testing-pgt-pgs-pgd-market/request-sampleFurther key findings from the report suggest:• Availability of a significant number of services related to early diagnosis of specific gene mutation in embryo marked the dominant position of PGD in 2018• Preimplantation Genetic Screening (PGS) seems to be reasonable intervention to enhance efficiency of selecting chromosomally normal embryo during IVF cycles.

The Global Preimplantation Genetic Testing Market 2020 explores the implications of a wide variety of factors influencing market drivers and growth.

In addition, this study reviews the global Preimplantation Genetic Testing Market wholesalers, channels of bargains, challenges, opportunities, boosters, potential examples, rate of change, market share, and status.A detailed analysis into the market position of Preimplantation Genetic Testing market competitiveness, benefits and downside of enterprise stock, industry growth patterns in the studied market, regional industrial layout attributes and economic policies, industry News and Strategies has been included.Get sample report@  https://www.kdmarketinsights.com/sample/6724The report covers segmentation analysis of Preimplantation Genetic Testing Market for better understanding and provides in-depth information on market outlook.

Important segments have been developed and analyzed to facilitate sound business decisions.

Each segment and its sub-segments are evaluated on the basis of their growth prospects, market share and CAGR.

This section reveals high-growth market segments and understands how the market will expand over the forecast period.Based on region, the global Preimplantation Genetic Testing market is segmented into:North America (U.S. & Canada)Europe (Germany, United Kingdom, France, Italy, Spain, Russia, and Rest of   Europe)Asia Pacific (China, India, Japan, South Korea, Indonesia, Taiwan, Australia, New Zealand, and Rest of Asia Pacific)Latin America (Brazil, Mexico, and Rest of Latin America)Middle East & Africa (GCC, North Africa, South Africa, and Rest of Middle East & Africa)Get Complete Research Report with TOC@ https://www.kdmarketinsights.com/product/6724/preimplantation-genetic-testing-marketRelevant points Highlighted:The report includes an overall business forecast that aims to gain valuable insights into the global Preimplantation Genetic Testing market.The main segments have been further classified into sub-segments for a detailed review and a deeper understanding of the industry.The factors leading to market growth have been listed.

The data has been collected from primary and secondary sources and analyzed by professionals in the field.The study analyses the latest trends and company profiles of the major players in the market.List of leading players:There are various players operating in the market.

A recent study on the global Preimplantation Genetic Testing market has projected the revenues to rise to the worth of ~US$ 200 million by the end of 2022.

The report highlights the key growth drivers and trends that will contribute to the growth momentum of the market.

The report provides an incisive analysis of the growth dynamics and quantitative assessment of the revenue potential in various regions and across key products, application/end-use industry, and technology segments.

It provides a comprehensive insight into the shares and sizes of the various segments in each year of the forecast period.

A comprehensive evaluation of recent investments by top players in the Preimplantation Genetic Testing market helps identify major research and development initiatives in the key regional markets.

The various assessments on the competitive landscape focus on the intensity of competition, entry barriers, PESTLE analysis, and key winning imperatives.

 The global preimplantation genetic testing market is expected to reach USD 107.3 million by 2024, at a CAGR of 6.2% over the forecast period, according to a new report by Grand View Research, Inc.

It is primarily driven by a rising awareness among couples to undergo diagnostic and screening tests to minimize genetic diseases and aneuploidy in fetus.

The ability of preimplantation genetic testing to detect genetic disorders and rare diseases, such as fibrodysplasia ossificans progressive, is anticipated to propel the growth.High adoption of In Vitro Fertilization (IVF) technique consequently upsurges the utilization of Preimplantation Genetic Diagnosis (PGD).

These techniques are advantageous in a way that they allow the development of a healthy fetus and prevent the risk of selective pregnancy termination.

Hence, PGT acts as an addendum to assisted reproductive technology.A substantial number of patients with infertility and impaired fecundity are recommended to embrace IVF therapy in combination with PGT procedures, which in turn is expected to stimulate the growth.

In addition, public and private authorities are promoting reproductive health by undertaking initiatives is also anticipated to drive the Preimplantation Genetic Testing (PGT) (PGS/PGD) market.Further key findings from the report suggest:Availability of a significant number of services related to early diagnosis of specific gene mutation in embryo marked the dominant position of PGD in 2018Preimplantation Genetic Screening (PGS) seems to be reasonable intervention to enhance efficiency of selecting chromosomally normal embryo during IVF cycles.